CONSORT 2010说明与详述:报告平行对照随机临床试验指南的更新

被引:111
作者
David Moher [1 ]
Sally Hopewell [2 ]
Kenneth F Schulz [3 ]
Victor Montori [4 ]
Peter C Gtzsche [5 ]
P J Devereaux [6 ]
Diana Elbourne [7 ]
Matthias Egger [8 ]
Douglas G Altman [2 ]
周庆辉
卞兆祥
刘建平
机构
[1] Ottawa Methods Centre,Clinical Epidemiology Program,Ottawa Hospital Research Institute,Ottawa Hospital,Ottawa,Ontario
[2] Centre for Statistics in Medicine, University of Oxford, Wolfson College
[3] Family Health International, Research Triangle Park
[4] UK Knowledge and Encounter Research Unit, Mayo Clinic, Rochester
[5] The Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej
[6] McMaster University Health Sciences Centre, Hamilton
[7] Medical Statistics Unit, London School of Hygiene and Tropical Medicine
[8] Institute of Social and Preventive Medicine (ISPM), University of
关键词
临床试验; 随机对照试验; 指南; CONSORT;
D O I
暂无
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
大量证据显示随机对照临床试验(randomised controlled trial,RCT)的报告质量不理想。报告不透明,则读者既不能评判试验结果是否真实可靠,也不能从中提取可用于系统综述的信息。最近的方法学分析表明,报告不充分和设计不合理与对治疗效果产生评价偏倚有关。这种系统误差对RCT损害严重,而RCT正是以其能减少或避免偏倚而被视为评价干预措施的金标准。为了提高RCT的报告质量,一个由专家和编辑组成的工作组制定了临床试验报告的统一标准(Consolidated Standards of Reporting Trials,CONSORT)声明。CONSORT声明于1996年首次发表,并于2001年更新。声明由对照检查清单和流程图组成,供作者在报告RCT时使用。许多核心医学期刊和主要国际性编辑组织都已认可CONSORT声明。该声明促进了对RCT的严格评价和解释。2001年,在对CONSORT进行修订时,人们就已经清楚地认识到,解释和说明制定CONSORT声明的原理,有助于研究人员等撰写或评价临床试验报告。一篇CONSORT说明与详述文章于2001年同2001版CONSORT声明一起发表。2007年1月的专家会议之后,对CONSORT声明作了进一步修订并已发表,即"CONSORT2010声明"。这次更新对原版对照检查清单作了文字上的修改,使其更为明晰,并收入了与一些新近才认识到的主题相关的建议,如选择性报告结局产生的偏倚。说明与详述文件旨在加强人们对CONSORT声明的理解、应用和传播,这次也作了大量修订,对每一项新增或更新的清单条目的含义和增改理由进行了解释,提供了优秀的报告实例,还尽可能地提供了相关的经验性研究的参考文献。文中收入了若干流程图实例。"CONSORT2010声明"、其说明与详述文件,以及相关网站(www.consort-statement.org),对于改进随机临床试验报告必将有所裨益。
引用
收藏
页码:701 / 741
页数:41
相关论文
共 81 条
[31]   Blinding and exclusions after allocation in randomised controlled trials: Survey of published parallel group trials in obstetrics and gynaecology [J].
Schulz, KF ;
Grimes, DA ;
Altman, DG ;
Hayes, RJ .
BRITISH MEDICAL JOURNAL, 1996, 312 (7033) :742-744
[32]  
Estimating Sample Sizes For Binary; Ordered Categorical; And Continuous Outcomes In Two Group Comparisons.[J].M. J. Campbell;S. A. Julious;D. G. Altman.BMJ: British Medical Journal.1995, 7013
[33]  
Absence Of Evidence Is Not Evidence Of Absence.[J].Douglas G. Altman;J. Martin Bland.BMJ: British Medical Journal.1995, 7003
[34]  
Somatostatin V Placebo In Bleeding Oesophageal Varices: Randomised Trial And Meta-Analysis.[J].Peter C. G?tzsche;Ida Gj?rup;Helen Bonnén;Niels Erik Bille Brahe;Ulrik Becker;Flemming Burcharth.BMJ: British Medical Journal.1995, 6993
[35]   THE RHETORIC OF RESEARCH [J].
HORTON, R .
BRITISH MEDICAL JOURNAL, 1995, 310 (6985) :985-987
[36]   THE NUMBER NEEDED TO TREAT - A CLINICALLY USEFUL MEASURE OF TREATMENT EFFECT [J].
COOK, RJ ;
SACKETT, DL .
BRITISH MEDICAL JOURNAL, 1995, 310 (6977) :452-454
[37]   THE IMPACT OF BLINDING ON THE RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED MULTIPLE-SCLEROSIS CLINICAL-TRIAL [J].
NOSEWORTHY, JH ;
EBERS, GC ;
VANDERVOORT, MK ;
FARQUHAR, RE ;
YETISIR, E ;
ROBERTS, R .
NEUROLOGY, 1994, 44 (01) :16-20
[38]   WHEN TO STOP A CLINICAL-TRIAL [J].
POCOCK, SJ .
BMJ-BRITISH MEDICAL JOURNAL, 1992, 305 (6847) :235-240
[39]  
Randomization; Statistics; and Causal Inference.[J].Sander Greenland.Epidemiology.1990, 6
[40]   THE RANDOMIZED CLINICAL-TRIAL - BIAS IN ANALYSIS [J].
MAY, GS ;
DEMETS, DL ;
FRIEDMAN, LM ;
FURBERG, C ;
PASSAMANI, E .
CIRCULATION, 1981, 64 (04) :669-673